Let's start with a major breakthrough in terms of treatment for COVID-19.
The Food and Drug Administration has given the green light to the emergency authorization of convalescent plasma for COVID-19 treatment.
The agency held off on the decision last week over concerns that evidence for its effectiveness was thin.
The treatment involves giving the sick antibody-rich plasma extracted from the blood of COVID-19 survivors.
According to the Mayo Clinic, the theory is that the antibodies should help recipients fight the virus.
Still, it's not clear what effect the FDA's decision will have in the convalescent plasma, which more than 70-thousand Americans have already received, largely outside randomized, controlled clinical trials that could prove effective.